DIN 02527138 — BREYANZI 120000000 CELLS
BREYANZI is a suspension of Lisocabtagene maraleucel marketed by BRISTOL-MYERS SQUIBB CANADA. The full Lisocabtagene maraleucel monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02527138
- Brand name
- BREYANZI
- Active ingredient
- Lisocabtagene maraleucel
- Strength
- 120000000 CELLS
- Dosage form
- SUSPENSION
- Route
- INTRAVENOUS
- Manufacturer
- BRISTOL-MYERS SQUIBB CANADA
- Health Canada status
- MARKETED
- Drug class
- CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.